Palau Pharma S.A. Report issue

For profit Phase 2
Founded: Barcelona Spain (2006)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2008
NCT00808977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

dersalazine (1 trial)

fluticasone (cutivate) (1 trial)

mesalamine (rowasa) (1 trial)

ur-63325 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4